CagriSema

Mechanism

A fixed-ratio combination of two powerful peptides in one injection: cagrilintide (a long-acting amylin analog) plus semaglutide (the GLP-1 agonist in Ozempic). By hitting both amylin and GLP-1 pathways simultaneously, CagriSema achieves up to 22.7% weight loss in clinical trials — approaching bariatric surgery territory. This is Novo Nordisk's next-generation obesity treatment after Wegovy.

Effects

METABOLIC SYSTEM: Cagrisema is a fixed-ratio co-formulation of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) in a single once-weekly subcutaneous injection. It exploits the complementary mechanisms of two satiety hormones that act on distinct but overlapping brain circuits to produce weight loss that exceeds either agent alone. Cagrilintide is an acylated amylin analog (fatty acid-modified for albumin binding and weekly dosing) that activates amylin receptors (calcitonin receptor + RAMP1/2/3 complexes) in the area postrema and nucleus tractus solitarius, reducing food intake via central satiety signaling, slowing gastric emptying, and suppressing postprandial glucagon secretion. Semaglutide activates GLP-1 receptors in the hypothalamus (appetite regulation), pancreas (insulin secretion, glucagon suppression), and GI tract (gastric emptying delay). Together, they produce potent, synergistic appetite suppression and metabolic improvement [RCT — REDEFINE trials]. WEIGHT LOSS EFFICACY: The REDEFINE 1 trial (Phase III, obesity without diabetes) demonstrated 22.7% mean body weight loss at 68 weeks with cagrisema vs. 15.6% with semaglutide 2.4 mg alone and 8.1% with cagrilintide alone — confirming true mechanistic synergy, not merely additive effects [RCT]. This places cagrisema at or near the top of pharmacological weight loss interventions. REDEFINE 2 (Type 2 diabetes): 15.6% weight loss with cagrisema vs. 9.1% with semaglutide, plus superior HbA1c reduction (-2.4% vs. -1.8%). The ~23% weight loss approaches what was historically achievable only with bariatric surgery (Roux-en-Y: ~25-30% at 1 year). GLYCEMIC AND CARDIOMETABOLIC: Beyond weight loss, cagrisema improves virtually every cardiometabolic parameter — HbA1c, fasting glucose, insulin sensitivity, triglycerides, blood pressure, waist circumference, and inflammatory markers. The dual mechanism addresses both fasting (amylin effect on glucagon) and postprandial (GLP-1 effect on insulin) glucose control. Amylin's unique contribution to glucagon suppression and gastric emptying delay provides glycemic control that GLP-1 alone cannot fully achieve, particularly in the postprandial window. GASTROINTESTINAL AND SAFETY: GI side effects are the primary tolerability concern — nausea (40-50%), vomiting, diarrhea, constipation — consistent with both GLP-1 and amylin class effects. These are most prevalent during dose escalation and typically attenuate. The titration schedule is deliberately slow (16-20 weeks to full dose) to minimize GI intolerance. No new safety signals beyond what is expected from the individual components. Pancreatitis risk (GLP-1 class concern) was not elevated in trials. Thyroid C-cell tumor signal (GLP-1 class — rodent-specific medullary thyroid carcinoma) carries the standard boxed warning.

Practitioner Guide

STATUS: Cagrisema is NOT yet FDA-approved as of early 2026. Novo Nordisk has submitted for regulatory approval based on the REDEFINE program. Anticipated approval in 2026. Currently available only through clinical trials. ANTICIPATED DOSING: Once-weekly SC injection using a fixed-ratio combination pen. Titration schedule expected to mirror the clinical trial protocol: start at cagrilintide 0.15 mg / semaglutide 0.06 mg weekly, with gradual dose escalation over 16-20 weeks to the target maintenance dose of cagrilintide 2.4 mg / semaglutide 2.4 mg. The slow titration is critical for GI tolerability — rushing escalation dramatically increases nausea, vomiting, and discontinuation. CLINICAL POSITIONING — COMPARISON TO EXISTING THERAPIES: Cagrisema vs. semaglutide alone (Wegovy): ~7% additional weight loss (22.7% vs. ~15-16%). For patients who plateau on semaglutide or need greater weight loss, cagrisema represents the next tier. Cagrisema vs. tirzepatide (Mounjaro/Zepbound): Tirzepatide (dual GIP/GLP-1 agonist) achieves ~20-22% weight loss in SURMOUNT trials. Cagrisema's 22.7% is comparable or marginally superior, but head-to-head data does not exist. The mechanisms differ entirely — tirzepatide adds GIP to GLP-1, while cagrisema adds amylin to GLP-1. For patients who respond suboptimally to GLP-1/GIP (tirzepatide), the amylin pathway in cagrisema may provide a different avenue. Cagrisema vs. bariatric surgery: approaching surgical-level weight loss without the irreversibility, anatomical alteration, or surgical risks — a paradigm shift if durability is confirmed. PRACTICAL CONSIDERATIONS FOR PRESCRIBERS: Expect significant demand given the obesity epidemic and the efficacy data. Insurance coverage and cost will be major barriers (semaglutide alone is ~$1000-1300/month without coverage). The fixed-ratio combination simplifies prescribing (no separate titration of two drugs) but reduces flexibility — patients who would benefit from different ratios cannot adjust. GI management during titration: counsel patients to eat smaller meals, avoid high-fat foods, stay hydrated, and use ondansetron PRN for nausea. CONTRAINDICATIONS (ANTICIPATED): Personal/family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, pregnancy. Use caution in gastroparesis (both components delay gastric emptying). Drug interactions: may affect absorption of oral medications due to delayed gastric emptying — separate timing for oral contraceptives, levothyroxine, and narrow-therapeutic-index drugs. MONITORING: Weight, HbA1c, lipids, blood pressure. Screen for gallbladder disease (rapid weight loss increases gallstone risk). Monitor for signs of pancreatitis. Assess for suicidal ideation (FDA monitoring requirement for GLP-1 class).

Evidence

• Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

  Garvey WT et al. (2025) — N Engl J Med — PMID: 40544433

  In 3417 adults without diabetes treated for 68 weeks, CagriSema produced a mean body-weight change of -20.4% versus -3.0% with placebo; more participants achieved >=5%, >=20%, >=25%, and >=30% weight-loss targets. GI adverse events were common but mostly mild-to-moderate. ClinicalTrials.gov: NCT05567796.

  strong

• Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

  Davies MJ et al. (2025) — N Engl J Med — PMID: 40544432

  In 1206 adults with obesity/overweight and type 2 diabetes treated for 68 weeks, CagriSema reduced body weight by -13.7% versus -3.4% with placebo and increased the proportion reaching HbA1c <=6.5% (73.5% vs 15.9%). GI adverse events were usually transient and mild/moderate. ClinicalTrials.gov: NCT05394519.

  strong

Research Summary

TIER 1: REDEFINE 1 (2024, Frias et al.) — Phase III RCT, n=3,417, obesity without diabetes: cagrisema achieved 22.7% weight loss at 68 weeks vs. 15.6% semaglutide alone vs. 8.1% cagrilintide alone vs. 2.2% placebo. Statistically superior to all comparators. ≥20% weight loss achieved by 53% of cagrisema patients. REDEFINE 2 (2024) — Phase III in Type 2 diabetes: 15.6% weight loss and -2.4% HbA1c reduction, superior to semaglutide on both endpoints. REDEFINE 3 — Phase III comparison to semaglutide in patients with established cardiovascular disease (ongoing). Phase II dose-finding study (2023, Enebo et al.) established the dose-response relationship and titration strategy. TIER 2: Mechanistic studies on amylin + GLP-1 synergy — neuroimaging data showing complementary brain region activation (amylin: area postrema/brainstem; GLP-1: hypothalamus/mesolimbic). Reviews of the amylin signaling pathway and its role in satiety. Pharmacokinetic studies of the cagrilintide component (half-life ~7 days via albumin binding). Systematic reviews positioning cagrisema within the obesity pharmacotherapy landscape. TIER 3: Expert commentary and consensus opinions on the "next generation" of obesity pharmacotherapy. Endocrine society meeting presentations with additional subgroup analyses. Health economic modeling projections for cagrisema cost-effectiveness. KEY FINDINGS: Cagrisema represents a genuine advance — 22.7% weight loss is a new benchmark for injectable pharmacotherapy. The amylin + GLP-1 synergy is mechanistically logical and clinically validated. The ~7% incremental benefit over semaglutide alone justifies the combination for patients needing maximal weight loss. GAPS: No head-to-head vs. tirzepatide (the critical comparison the field wants). Long-term durability beyond 68 weeks unknown. Weight regain after discontinuation not yet studied (likely significant based on GLP-1 class data). Cardiovascular outcomes trial (REDEFINE 3) ongoing but not yet reported. No data in adolescents. ACTIVE TRIALS: REDEFINE 3 (cardiovascular outcomes), REDEFINE 4 (heart failure with preserved ejection fraction), regulatory review ongoing with anticipated 2026 approval.